Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium sulphate for fetal neuroprotection before preterm birth at 30 to 34 weeks
ACTRN12611000491965Phase 3Completed
- Sponsor
- University of Adelaide
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in preterm birth comparing Magnesium sulphate with Placebo (2 arms). Primary endpoint: Death or cerebral palsy. Started Jan 2012; status: completed.
02
Drugs
magnesium sulfate
03
Conditions
preterm birth
Beyond the preview
Go deeper on ACTRN12611000491965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000491965.